Centogene N.V.

General information

Centogene N.V.
Am Strande 7
18055 Rostock, Mecklenburg-Vorpommern
Germany

Contact person: Peter Bauer, Chief Genomic Officer
Company main phone: +49 (381) 80113400
Company main fax: +49 (381) 80113401
Website: https://www.centogene.com

Year founded:	2006
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 444

Corporate description / mission:
Centogene N.V. is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. The company provides the full spectrum of modern methods and technology for human genetics analysis. The company also active in research and is constantly developing new products for human genetics.

State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2019

Categorization

Sector:

Biotechnology - R&D Services

Subsector:

Analytical services
Bioinformatics
Diagnostic services
Genomics

Primary therapeutic areas:

Cardiovascular / cardiology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the ear / otology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
Genitourinary system / Urology
Musculoskeletal system and connective tissue / Orthopedics
Neoplasms / cancer / oncology
Respiratory / pulmonology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

R&D
Service company
Supplier / Distributor

Customer segments:

Other
Consumers (mass market)
Hospitals
Physicians / doctors

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Description of products:
Prenatal Testing
Newborn testing
Metabolic Testing
Hereditary Cancer Testing, etc.

Financing details

Fiscal year (end of) 2022

Revenues:	USD 47.47M
R&D expenses:	USD 17.49M

No. of shares:	27'865'800
Market cap. / valuation:	USD 31.49M